BioNTech tops Q3 expectations – the stock is up
8 November 2022BioNTech SE (NASDAQ:BNTX) reported its third quarter financial results on Monday.
The German pharmaceutical company beat both revenue and earnings per share (EPS) estimates for the quarter, sending the stock price higher.
The company reported revenue of $3.392 billion vs. $2.024 billion expected.
EPS reported at $6.841 per share vs. $3.352 per share estimate.
”Thanks to our strong execution in the third quarter of 2022, we updated our COVID-19 vaccine revenue guidance for the year 2022 to the upper end of the original range. We started shipments of our Omicron-adapted bivalent vaccines early in September and we expect to carry on with our deliveries throughout the fourth quarter of 2022,” Jens Holstein, CFO of BioNTech commented on the latest results.
”We believe in the potential of our COVID-19 franchise and plan to build on our leading position with ongoing innovations in this field. The power of our scientific innovation combined with our strong financial position allows us to accelerate and expand our diversified clinical pipeline and to create future growth in the interest of all stakeholders,” Holstein concluded.
The stock was up by around 2% during the session on Monday following the latest results, trading at $155.52 a share.
Stock performance
- 1 month: +16.38%
- 3 months: -7.00%
- Year-to-date: -38.93%
- 1 year: -35.10%
BioNTech price targets
- JPMorgan: $132
- Deutsche Bank: $250
- HC Wainwright & Co.: $272
- SVB Leerink: $224
- Morgan Stanley: $194
- Goldman Sachs: $206
BioNTech SE is the 411th largest company in the world with a market cap of $38.46 billion.
You can trade BioNTech SE (NASDAQ:BNTX) and many other stocks from the NYSE, NASDAQ, HKEX, ASX, LSE and DE with GO Markets as a Share CFD.
Sources: BioNTech SE, TradingView, Benzinga, CompaniesMarketCap
Disclaimer: Articles are from GO Markets analysts and contributors and are based on their independent analysis or personal experiences. Views, opinions or trading styles expressed are their own, and should not be taken as either representative of or shared by GO Markets. Advice, if any, is of a ‘general’ nature and not based on your personal objectives, financial situation or needs. Consider how appropriate the advice, if any, is to your objectives, financial situation and needs, before acting on the advice. If the advice relates to acquiring a particular financial product, you should obtain and consider the Product Disclosure Statement (PDS) and Financial Services Guide (FSG) for that product before making any decisions.
Next Article
China in Covid 19 limbo creating headwind for the global economy?
In recent days and weeks there have been rumours that China is beginning to consider an easing of its Covid restrictions. As virtually the last country with extreme Covid restrictions, a shift in policy from China would be a major catalyst for the global markets and economy. Whilst the CCP has not yet announced any actual easing, there are hopes th...
Previous Article
The Week Ahead – US Mid-terms set stage for another volatile week
Another week done, another roller coaster for equity and risk markets as the bulls and the bears battled to take control of the narrative in a data ri...